Hosted on MSN1d
Intellia Loses 21.6% in a Week: How Should You Play the Stock?
Intellia Therapeutics, Inc. NTLA lost 21.6% in a week as investors were disappointed with the company’s plans for portfolio ...
Hennion & Walsh Asset Management Inc. Has $1.41 Million Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Hennion & Walsh Asset Management Inc. lifted its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 125.2 ...
Editas And Intellia: Strategic Shifts And Long-Term Investment Potential
A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.
Hosted on MSN5d
Intellia slashes workforce by 27% to focus on late stage CRISPR candidates
Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.
STAT8d
Intellia cuts 27% of staff, in the latest wave of gene-editing layoffs
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
FierceBiotech9d
Intellia, citing 'challenging market environment,' lays off 27% of staff as it takes ax to pipeline
Intellia Therapeutics is starting off 2025 with a significant head count reduction as it tosses out pipeline assets to keep ...
Intellia cuts 27% of workforce as it eyes commercial launch
Intellia Therapeutics Inc. is shedding employees and paring down its pipeline as it transforms from a late-stage development ...
bovnews1d
What’s Fueling Intellia Therapeutics Inc (NTLA) Stock’s -53.57% Loss Below Its 200-Day SMA?
Intellia Therapeutics Inc (NTLA) stock saw a decline, ending the day at $9.42 which represents a decrease of $-0.29 or -2.99% from the prior close of $9.71. The stock opened at $9.76 and touched a low ...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Intellia Therapeutics, Inc. (NTLA) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESSWIRE / January 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...
Intellia Therapeutics: Buying The Path To Commercialization
Financial writer recommends buying Intellia Therapeutics, Inc. stock as it restructures, focusing on late-stage programs for ...
Why Is Intellia Therapeutics Stock Trading Lower On Friday?
Intellia Therapeutics Inc (NASDAQ:NTLA) outlined its strategic priorities for 2025, emphasizing the acceleration of ...
AdvisorNet Financial Inc Buys 4,950 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)
AdvisorNet Financial Inc grew its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 96.4% during the 4th quarter, HoldingsChannel reports. The fund owned 10,085 shares of the company ...